Grafa News and Videos — Page 71

Johnson & Johnson (NYSE:JNJ) reported five-year CARTITUDE-2 study results showing that 10 of 20 patients treated with CARVYKTI remained alive and progression-free without maintenance therapy after receiving a single infusion.

Merck (NYSE:MRK) and Eisai received U.S. Food and Drug Administration approval for the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) to treat adults with advanced clear cell renal cell carcinoma after PD-1 or PD-L1 inhibitor therapy.

Duke Energy (NYSE:DUK) appointed Joyce Mullen to its board of directors effective September 28, 2026, with Mullen joining the Audit Committee and Operations and Nuclear Oversight Committee.

Addex Therapeutics (NASDAQ:ADXN) announced it regained full global rights to its GABAB positive allosteric modulator assets from Indivior UK, including a development candidate previously selected under their research collaboration.

Johnson Outdoors (NASDAQ:JOUT) announced that its board of directors approved a quarterly cash dividend of $0.33 per Class A share and $0.30 per Class B share, payable on October 23, 2026.

Vertical Aerospace (NYSE:EVTL) opened a dedicated Aircraft Assembly Centre at its Cotswold Airport Flight Test Centre, adding 60,000 square feet of manufacturing space to support the development and production of its Valo electric vertical take-off and landing aircraft.

Akamai Technologies (NASDAQ:AKAM) shares rose 21% premarket after the company signed an $11.6 billion, seven-year cloud services agreement with AI company Anthropic, with the deal including a warrant that could allow Anthropic to acquire a stake of up to 5% in Akamai.

WhiteHawk Minerals Corp. (NYSE:WHK) announced the closing of approximately $111.8 million in acquisitions, including the $105 million purchase of Marcellus, Utica, and Haynesville Shale natural gas mineral and royalty assets from San Jacinto Minerals II.

Oil prices moved lower on Friday as investors balanced expectations for possible progress in US-Iran negotiations against concerns that continued attacks in the Middle East could disrupt crude supplies.

REGENXBIO (NASDAQ:RGNX) announced three-year Phase II results from the ALTITUDE clinical trial evaluating investigational sura-vec for non-proliferative diabetic retinopathy (NPDR).